Axsome Therapeutics, Inc. (AXSM) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は New York City, NY, アメリカ. 現CEOは Herriot Tabuteau.
AXSM を有する IPO日 2015-11-19, 712 名の正社員, に上場 NASDAQ Global Market, 時価総額 $9.42B.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders. The company's lead candidate, AXS-05, is being evaluated for major depressive disorder, treatment-resistant depression, Alzheimer's disease agitation, and smoking cessation across Phase II and Phase III clinical trials. Its pipeline also includes AXS-07 for acute migraine treatment, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, all in late-stage development. Founded in 2012 and headquartered in New York, Axsome collaborates with leading institutions including Duke University to advance its clinical programs.
